Cathie Wood cuts two consecutive days of stocks! She sells another approximately 58,000 shares of NVIDIA on Friday

Ark Invest sold additional shares of NVIDIA over 58,000 (about $10 million) and about 20,000 shares of AMD (about $3.9 million) again on Friday (3/28). The only purchase was the biotech company Arcturus Therapeutics. Combined with Thursday’s large-scale de-risking, the two days cleared more than $100 million in AI chip and technology holdings.
(Background: the female stock guru unloads! Ark Invest dumped tens of millions of dollars in Meta and Nvidia shares, while also trimming its own Bitcoin ETF)
(Additional context: the U.S. stock earnings season is here—what Cathie Wood at Ark and Pelosi are positioning for)

After Friday’s market close, ARK Invest’s trading records show that Cathie Wood made another move. This time, across the three ETFs ARKK, ARKW, and ARKF, it sold 58,119 shares of NVIDIA, equivalent to about $10 million; it also sold 19,126 shares of AMD, about $3.9 million. In the entire operation, the only purchase was Arcturus Therapeutics (ARCT), the biotech company, buying 48,659 shares for about $344,000.

The Friday figures aren’t surprising, but when you add Thursday (3/27) and combine the two days, Ark’s NVIDIA trimmed holdings totaled more than 212,000 shares, about $36.5 million; AMD was reduced by more than 57,000 shares, about $11.7 million; tech stocks plus crypto ETFs together cleared more than $100 million over two days.

The only buy was biotech—did ARK pivot?

In these two days of trading, ARK’s big tech holdings were nearly all sell-oriented. The only buy on Friday, Arcturus Therapeutics, is an RNA therapy company in an entirely different field from AI chips.

Looking at past positions, since this year began, ARK has been sharply increasing exposure to gene editing and genetics (genomics). For example, Beam Therapeutics has become a recent key focus for ARK.

Cathie Wood said externally that she expects production productivity growth to accelerate to 4–6% in 2026, but the driver isn’t compute power—it’s innovation in biomedicine.